In 2015, CryoHoldco acquired three key brands in the stem cell sector in Mexico. The first was CryoCell de México, which has more than 20 years of operation and was acquired from CryoCell Internacional, positioning it as a world leader. The second acquisition was BCU, Banco del Cordón Umbilical, a leader in the collection of stem cells from the umbilical cord and blood, focused on the country's central area. Finally, BSCU, the Blood and Umbilical Cord Bank, was acquired. It is a premium brand of Grupo Ángeles and is now exclusive to Hospitales Ángeles, operating in the seven most essential locations of the Mexican hospital group.

CryoHoldco has expanded its presence in Colombia by acquiring STEM, the country's leading regenerative medicine company, and the Redcord bank. This strategic move also reflects a greater focus on Research and Development.

CryoHoldco began gaining international recognition and continued its expansion in Peru by purchasing Criocord and Lazo de Vida, both leading Peruvian cryopreservation companies.

CryoHoldco exceeds the storage of more than 200,000 samples, consolidating itself as the sixth largest company worldwide in the stem cell sector. This milestone reflects its sustained growth and leadership in the global biotechnology industry.

CryoHoldco expands in Argentina with the acquisition of Biocells, consolidating its presence in the Latin American market. The company launches cutting-edge genetic services and exceeds 15,000 annual processes, reaffirming its industry leadership and commitment to innovation and quality in the biotechnology sector.

CryoHoldco expands its product portfolio by launching clinical COVID testing services using Q-PCR, which is approved by both the FDA and INDRE. In addition, the company manages clinical trials in various countries for the treatment of COVID-19 using mesenchymal stem cells derived from Wharton's jelly. This development underlines its commitment to innovation in the health field and its ability to respond to global health emergencies.

CryoHoldco reaches a significant milestone by exceeding the safeguarding of more than 300,000 samples, consolidating itself as the fifth largest company worldwide in the stem cell sector and the leader in Latin America. To strengthen its presence in the region, it acquired two prominent Brazilian companies: CordVida and CordCell based in São Paulo,

CryoHoldco makes a significant foray into developing new products by launching new business lines focused on genetics. It introduces the NIPT (Not Invasive Prenatal Test) and various advanced genetic tests (Origins and Ancestry, Nutrition and Sports, Longevity and Skin, Personality, Pharmacogenetics, Health and Prevention).

Partnership with Veritas:
Veritas is a leader in secure multicloud data management. Their partnership with Kyndryl, the largest provider of IT infrastructure services, has led to joint solutions like the Kyndryl Data Protection Risk Assessment and Kyndryl Incident Recovery, focused on IT resilience and data protection.

CryoHoldco changes course, evolves, and invites Mario Godínez as the new CEO. Mario puts together a solid infrastructure, a team of world-class professionals and scientists. The company soon became an undisputed leader in the field of regenerative medicine in Mexico. With significant investments in research and development, the company begins to explore new frontiers in regenerative medicine, working on pioneering treatments for degenerative diseases, autoimmune diseases, and genetic disorders.

Launch FCells. Leading brand in cellular rejuvenation and dermocosmetics in Latin America, which offers a unique treatment based on fibroblasts and mesenchymal cells.

Partnership with ADNTRO:
ADNTRO provides genetic testing through saliva samples, offering insights into ancestry, nutrition, sports, longevity, and personality. They use Illumina’s “Global Screening Array,” which analyzes 700,000 genetic markers with 99% confidence.

Renew Therapies Launch

The future of medicine, bringing patients and physicians the opportunity to experience it today.

Renew Therapies will transform healthcare with next-generation, personalized regenerative therapies powered by mesenchymal stem cells for national and international patients

Renew Therapies is the ideal alternative to conventional treatments, elevating medicine to the next level with a steadfast commitment to medical excellence and extraordinary results, always focused on providing an exceptional patient experience.